Qian Shi

Erroneous Sentence Removed From Article.

S. Alberts, F. Sinicrope, Qian Shi, 2017, JAMA oncology.

Error in Author Degree.

S. Alberts, F. Sinicrope, Qian Shi, 2017, JAMA dermatology.

Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma

Nguyen H. Tran, M. Borad, T. Bekaii-Saab, 2022, Targeted Oncology.

Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.

A. Benson, J. Galon, R. Goldberg, 2022, JCO precision oncology.

Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab

F. Sinicrope, R. McWilliams, J. Jones, 2023, JAMA network open.

Completion of Genetic Testing and Incidence of Pathogenic Germline Mutation among Patients with Early-Onset Colorectal Cancer: A Single Institution Analysis

F. Sinicrope, A. Jatoi, A. Mahipal, 2023, Cancers.

Genome‐wide study of genetic polymorphisms predictive for outcome from first‐line oxaliplatin‐based chemotherapy in colorectal cancer patients

J. Chang-Claude, M. Hoffmeister, P. Seibold, 2023, International journal of cancer.

Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).

T. Smyrk, N. Foster, S. Alberts, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.